Glucocorticoid therapy in inflammatory bowel disease: mechanisms and clinical practice

S Bruscoli, M Febo, C Riccardi, G Migliorati - Frontiers in immunology, 2021 - frontiersin.org
Inflammatory bowel disease (IBD) comprises ulcerative colitis (UC) and Crohn's disease
(CD). IBD etiopathology is multifactorial and involves alteration of immune cells and chronic …

Resolution of inflammation: what controls its onset?

MA Sugimoto, LP Sousa, V Pinho, M Perretti… - Frontiers in …, 2016 - frontiersin.org
An effective resolution program may be able to prevent the progression from non-resolving
acute inflammation to persistent chronic inflammation. It has now become evident that …

More than suppression: glucocorticoid action on monocytes and macrophages

JM Ehrchen, J Roth, K Barczyk-Kahlert - Frontiers in immunology, 2019 - frontiersin.org
Uncontrolled inflammation is a leading cause of many clinically relevant diseases. Current
therapeutic strategies focus mainly on immunosuppression rather than on the mechanisms …

Glucocorticoids, sex hormones, and immunity

O Bereshchenko, S Bruscoli, C Riccardi - Frontiers in immunology, 2018 - frontiersin.org
Glucocorticoid hormones regulate essential body functions in mammals, control cell
metabolism, growth, differentiation, and apoptosis. Importantly, they are potent suppressors …

Mediators of the resolution of the inflammatory response

MA Sugimoto, JP Vago, M Perretti, MM Teixeira - Trends in immunology, 2019 - cell.com
The termination of inflammation is governed by endogenous molecules collectively referred
to as 'mediators of resolution'of inflammation. There is now strong evidence to suggest that …

Resolution pharmacology: focus on pro-resolving annexin A1 and lipid mediators for therapeutic innovation in inflammation

M Perretti, J Dalli - Annual Review of Pharmacology and …, 2023 - annualreviews.org
Chronic diseases that affect our society are made more complex by comorbidities and are
poorly managed by the current pharmacology. While all present inflammatory …

From NSAIDs to glucocorticoids and beyond

A Sinniah, S Yazid, RJ Flower - Cells, 2021 - mdpi.com
Our interest in inflammation and its treatment stems from ancient times. Hippocrates used
willow bark to treat inflammation, and many centuries later, salicylic acid and its derivative …

[HTML][HTML] Resolving inflammation by TAM receptor activation

JP Vago, FA Amaral, FAJ van de Loo - Pharmacology & Therapeutics, 2021 - Elsevier
The control of inflammation is strictly regulated to ensure the adequate intensity and duration
of an inflammatory response, enabling the removal of the trigger factors and the restoration …

Glucocorticoids and COVID-19

S Bruscoli, PG Puzzovio, M Zaimi, K Tiligada… - Pharmacological …, 2022 - Elsevier
Abstract Coronavirus Disease 19 (COVID-19) is associated with high morbidity and mortality
rates globally, representing the greatest health and economic challenge today. Several …

GILZ as a mediator of the anti-inflammatory effects of glucocorticoids

S Ronchetti, G Migliorati, C Riccardi - Frontiers in endocrinology, 2015 - frontiersin.org
Glucocorticoid-induced leucine zipper (GILZ) is a dexamethasone-inducible gene that
mediates glucocorticoid (GC) actions in a variety of cell types, including many cells of …